Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM.H

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform technology. It specializes in stabilizing carbohydrate molecules. It is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two advanced programs are the cosmetic skin lightener and diabetes drug. Other projects include the development of an anti-aging / cell protection library, a novel anti-wrinkle compound, and the launch of an anti-viral program. Its TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its subsidiary is TFChem S.A.R.L.


TSXV:SBM.H - Post by User

User Avatar Image
(3)
•••
  • 23minus7X
Comment by 23minus7on Sep 13, 2025 6:16am
58 Views
Post# 36713114

RE:Does it really matter?

RE:Does it really matter?Ante mortem, or the patient's last gasp. 
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities